

# SCI PHARMTECH, INC. 旭富製藥科技

## 簡報

ISO 14001

BUREAU VERITAS  
Certification



ISO 9001

BUREAU VERITAS  
Certification



## 公司概況Profile

- 員工數Employee：255
- 設立日期：中華民國七十六年九月十八日  
Date of establishment: Sep. 18, 1987
- 資本額Capital：新台幣1,195佰萬元(NTD 1,195mn)
- 營業項目Business：
  - 原料藥API（59.65%）
  - 中間體Intermediate（39.17%）
  - 其他 Other chemicals（1.18%）

## 產品組合-Products

Sales Product	%	2023Y ( K NT\$)
PGA	26.0%	313,184
VA series	25.2%	303,219
Pent-2 / PEB.Na	24.4%	293,838
BZA	8.3%	100,190
Dulo.Hcl	5.4%	65,168
PF.Hcl	4.0%	47,786

## 營運概況-IS

Unit: K NTD


	2023.Q1~Q3
營收Sales	912,743
營業成本COGS	(629,815)
毛利Gross Profit	282,928
毛利率 GP Ratio	31.0%
營業費用Operating Expenses	(131,539)
營業利益Operating Income	151,389
營業外損益Non-Operating In/Ex	223,094
稅前淨利 Net Profit before Tax	374,483
所得稅Income Tax	(76,151)
本期淨利Net Profit after Tax	298,332

## Pyrogallolaldehyde (PGA)

Benserazide

治療帕金森氏症之中間體


Intermediate for Parkinson's Disease



## VA Series:

### Valproic Acid, Divalproex Sodium, Sodium Valproate


- 適應症 Application :  
癲癇(seizure)、躁鬱症(bipolar disorder)、  
偏頭痛(migraine headaches)



## Pent-2 / Pentobarbital Sodium

鎮定安眠用中間體及原料藥


Intermediate and API for calmative



## Brinzolamide

- 青光眼原料藥

API for Glaucoma medication






## Duloxetine HCl

- 適應症 Application:


重鬱症(major depressive disorder)、廣泛性焦慮症  
(generalized anxiety disorder)、糖尿病週邊神經痛  
(diabetic neuropathy)、纖維肌痛 (Fibromyalgia)、  
慢性腰痛(日本地區) lower back pain (only in Japan)



## Hydroxychloroquine sulfate

- 適應症 Application:

類風濕性關節炎(rheumatoid arthritis)、瘧疾(malaria)、慢性多形性日光疹、慢性圓板狀紅斑症(discoid and systemic lupus erythematosus)



## 新品項(New Products)

- Buprenorphine  
止痛劑(Painkiller) 、治療鴉片類物質成癮 (Opioid use addiction)
- LMTM  
阿茲海默症藥物(Alzheimer's disease medicine)
- 大麻二酚 Cannabidiol  
癲癇藥物 (Epidiolex)
- 嗜睡症藥物 (Narcolepsy)
- 腺嘌呤 (Adenine)
- Pimobendan  
寵物心臟病藥物(Heart disease medicine for pets)

## 觀音廠&法蘭摩沙(Guanyin Plant and Framosa)

預計2025年量產

Both will be commercialized in 2025



General View



簡報完畢



敬請指教